A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis

Overview of attention for article published in American Journal of Obstetrics & Gynecology, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 16 news outlets
policy: 1 policy source
twitter: 15 X users

facebook: 1 Facebook page
guideline: 2 clinical guideline sources

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 31 X posts from 15 X users, with an upper bound of 48,001 followers.

RT @TripPrimaryCare: New2Trip: Phase-3, double-blind, placebo-controlled study of effectiveness & safety of single oral doses of se… https:…

New2Trip: Phase-3, double-blind, placebo-controlled study of effectiveness & safety of single oral doses of se… https://t.co/aIKNohjZkk

New2Trip: Phase-3, double-blind, placebo-controlled study of effectiveness & safety of single oral doses of se… https://t.co/CKV7eJfV7S

New2Trip: Phase-3, double-blind, placebo-controlled study of effectiveness & safety of single oral doses of se… https://t.co/aIKNohjZkk

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 27 additional X posts.